Skip to main content

Table 5 Toxicities associated with treatment

From: Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study

toxicities

CCRT(N = 55)

chemotherapy(N = 86)

 

Gr.1

Gr.2

Gr.3

Gr.4

≥Gr. 3

Gr.1

Gr.2

Gr.3

Gr.4

≥Gr. 3

P

Leucocytopenia

11 (20.0%)

17 (30.9%)

19 (34.5%)

4 (7.3%)

41.8%

19 (22.1%)

43 (50.0%)

16 (18.6%)

5 (5.8%)

24.4%

0.040

Thrombocytopaenia

27 (49.1%)

12 (21.8%)

6 (10.9%)

0 (0.0%)

10.9%

45 (52.3%)

24 (27.9%)

7 (8.1%)

1 (1.2%)

9.3%

0.779

Anemia

37 (67.3%)

9 (16.4%)

1 (1.8%)

0 (0.0%)

1.8%

52 (60.5%)

15 (17.4%)

1 (1.2%)

0 (0.0%)

1.2%

0.647

Nausea/vomiting

28 (50.9%)

16 (29.1%)

2 (3.6%)

0 (0.0%)

3.6%

47 (54.7%)

16 (18.6%)

6 (7.0%)

0 (0.0%)

7.0%

0.483

liver injury

6 (10.9%)

1 (1.8%)

0 (0.0%)

0 (0.0%)

0%

10 (11.6%)

2 (2.3%)

0 (0.0%)

0 (0.0%)

0%

treatment-related pneumonitis

19 (34.5%)

7 (12.7%)

4 (7.3%)

0 (0.0%)

7.3%

 

treatment-related esophagitis

24 (43.6%)

16 (29.1%)

8 (14.5%)

0 (0.0%)

14.5%

 

  1. Abbreviations: CCRT concurrent chemoradiotherapy, Gr grade